Bright Minds Biosciences Inc. (DRUG) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Bright Minds Biosciences Inc. (DRUG) closed at USD 50.71 on 2026-10-14, a change of -11.7 % over the past year, with a market capitalization of USD 534.73M.

Bright Minds Biosciences Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Bright Minds Biosciences Inc. key figures

Previous close

USD 50.71 (2026-10-14)

1-year change

-11.7 %

Market cap

USD 534.73M

Enterprise value

USD 226.97M

P/E ratio (trailing)

-26.84

P/E ratio (forward)

-9.50

EPS (trailing)

-2.02

EPS (forward)

-5.71

PEG ratio

n/a

Price to book

2.47

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.72

Employees

26

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company's BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Bright Minds Biosciences Inc. and compare it with other stocks.